首页> 外文期刊>Annals of nuclear medicine >Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity.
【24h】

Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity.

机译:靶向细胞表面蛋白FZD10的实体瘤的放射免疫疗法:治疗效果很大程度上取决于放射敏感性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Frizzled homolog 10 (FZD10) is expressed at high levels on the cell surface of almost all synovial sarcoma tissues, but is absent in most normal organs. In a previous study, yttrium-90 ((90)Y)-labeled anti-FZD10 antibody (MAb 92-13) showed considerable therapeutic efficacy in synovial sarcoma cell-bearing mice. The purpose of the present study was to elucidate the factors associated with this therapeutic efficacy of (90)Y-MAb 92-13. METHODS: FZD10 expression levels of SYO-1 (FZD10-overexpressing synovial sarcoma cell line) and DLD-1/FZD10 (FZD10-transfected DLD-1 cell) were determined by the cell binding assay, and their radiosensitivity was evaluated by incubation with (90)Y-MAb 92-13 in vitro. Biodistribution study of indium-111 ((111)In)-MAb 92-13 was performed in SYO-1 and DLD-1/FZD10 tumor-bearing mice. For therapeutic studies, SYO-1 and DLD-1/FZD10 tumor-bearing mice were treated with (90)Y-MAb 92-13 (100, 150, and 200 muCi), after which the change in tumor volume was measured. Immunohistochemical staining was performed on the excised tumor. RESULTS: Expression level of FZD10 on DLD-1/FZD10 was much greater than that on SYO-1. The accumulation of (111)In-MAb 92-13 was much higher in DLD-1/FZD10 tumor-bearing mice than in SYO-1 tumor-bearing mice (49.0 +/- 4.2 and 22.0 +/- 4.5% ID/g, respectively, at 48 h after administration). In SYO-1 tumor, substantial tumor size reduction was observed in all mice treated with (90)Y-MAb 92-13 (tumor volume decreased to less than 0.1 cm(3) at 11 days after treatment) and tumor regrowth was not observed in most of them. In contrast, only slow progression was observed in DLD-1/FZD10 tumor. When incubated with (90)Y-MAb 92-13, high radioactivity was needed to damage DLD-1/FZD10. Immunohistochemical study indicated apoptosis of SYO-1 tumor. CONCLUSIONS: The therapeutic efficacy of RIT seems to largely depend on the tumor radiosensitivity.
机译:目的:卷曲的同源物10(FZD10)在几乎所有滑膜肉瘤组织的细胞表面高水平表达,但在大多数正常器官中却不存在。在以前的研究中,钇90((90)Y)标记的抗FZD10抗体(MAb 92-13)在滑膜肉瘤细胞小鼠中显示出可观的治疗功效。本研究的目的是阐明与(90)Y-MAb 92-13的这种治疗功效相关的因素。方法:通过细胞结合实验确定SYO-1(过表达FZD10的滑膜肉瘤细胞系)和DLD-1 / FZD10(FZD10转染的DLD-1细胞)的FZD10表达水平,并通过与( 90)Y-MAb 92-13体外。铟111((111)In)-MAb 92-13的生物分布研究在SYO-1和DLD-1 / FZD10荷瘤小鼠中进行。为了进行治疗研究,将SYO-1和DLD-1 / FZD10荷瘤小鼠用(90)Y-MAb 92-13(100、150和200μCi)处理,然后测量肿瘤体积的变化。对切​​除的肿瘤进行免疫组织化学染色。结果:DLD-1 / FZD10上FZD10的表达水平明显高于SYO-1。 (111)In-MAb 92-13的积累在DLD-1 / FZD10荷瘤小鼠中比在SYO-1荷瘤小鼠中高得多(49.0 +/- 4.2和22.0 +/- 4.5%ID / g分别在给药后48小时)。在SYO-1肿瘤中,在用(90)Y-MAb 92-13治疗的所有小鼠中均观察到肿瘤大小显着减少(治疗后11天肿瘤体积降至0.1 cm(3)以下),未观察到肿瘤再生长在大多数情况下。相反,在DLD-1 / FZD10肿瘤中仅观察到缓慢进展。与(90)Y-MAb 92-13孵育时,需要高放射性来破坏DLD-1 / FZD10。免疫组织化学研究表明SYO-1肿瘤的凋亡。结论:RIT的疗效似乎在很大程度上取决于肿瘤的放射敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号